6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-2-carbaldehyde | 843657-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-2-carbaldehyde
• CAS: 843657-69-2
• 化学式: C₁₃H₁₂FNO
• 分子量: 217.243
• InChiKey: DUKBPYWGRKKAOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-2-carbaldehyde 、 aplindore 在 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 生成
  参考文献：
  名称：

  Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia

  摘要：

  A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D-2 receptor ligands in an attempt to identify potent D-2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D-2 partial agonism in cell-based and in vivo assays. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.050
• 作为产物：
  描述：

  (6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-2-yl)methanol 在 三氧化硫吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-2-carbaldehyde
  参考文献：
  名称：

  Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia

  摘要：

  A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D-2 receptor ligands in an attempt to identify potent D-2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D-2 partial agonism in cell-based and in vivo assays. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.050

文献信息

• [EN] 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES<br/>[FR] DERIVES 3-AMINO CHOMANE ET 2-AMINO TETRALINE
  申请人：WYETH CORP

  公开号：WO2005012291A1

  公开（公告）日：2005-02-10

  3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

  揭示了3-氨基色苷和2-氨基四氢萘衍生物以及含有这些化合物的组合物。还揭示了在治疗血清素失调症，如抑郁症和焦虑症中使用3-氨基色苷和2-氨基四氢萘化合物以及含有这些化合物的组合物的方法。
• 3-Amino chroman and 2-amino tetralin derivatives
  申请人：Hatzenbuhler Theriault Nicole

  公开号：US20050032873A1

  公开（公告）日：2005-02-10

  3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

  本文披露了3-氨基色满和2-氨基四氢萘衍生物及含有这些化合物的组合物。还披露了使用3-氨基色满和2-氨基四氢萘化合物及含有这些化合物的组合物治疗血清素失调症，如抑郁和焦虑的方法。
• 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES
  申请人：Wyeth

  公开号：EP1651637A1

  公开（公告）日：2006-05-03
• Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
  作者：David P. Rotella、Geraldine R. McFarlane、Alexander Greenfield、Cristina Grosanu、Albert J. Robichaud、Rajiah Aldrin Denny、Rolf W. Feenstra、Sara Núñez-García、Jan-Hendrik Reinders、Martina van der Neut、Andrew McCreary、Chris G. Kruse、Kelly Sullivan、Farhana Pruthi、Margaret Lai、Jean Zhang、Dianne M. Kowal、Tikva Carrick、Steven M. Grauer、Rachel L. Navarra、Radka Graf、Julie Brennan、Karen L. Marquis、Mark H. Pausch

  DOI：10.1016/j.bmcl.2009.08.050

  日期：2009.10

  A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D-2 receptor ligands in an attempt to identify potent D-2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D-2 partial agonism in cell-based and in vivo assays. (C) 2009 Elsevier Ltd. All rights reserved.